ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2026
An Anti-Cell Adhesion Molecule 1 Antibody Improves Mite Antigen-Induced Atopic Dermatitis-Like Lesions and Pruritus in NC/Nga Mice.
Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn atopic dermatitis, skin scratching leads to worsening of the dermatitis. Cell adhesion molecule 1 (CADM1), an immunoglobulin superfamily member, is highly expressed in peripheral nerve fibers, and the anti-CADM1 antibody 3E1 preferentially localizes to dermal nerve fibers upon subcutaneous injection and exerts analgesic effects. Whether 3E1 improves atopic dermatitis-like lesions and pruritus was examined in NC/Nga mice. SUBJECTS AND
methodsThe systemic distribution of 3E1 after intravenous injection was examined using indocyanine green imaging, immunostaining, and Western blotting techniques. Atopic dermatitis-like lesions were created by repeated application of the mite antigen Biostir. 3E1 was then administered subcutaneously at the lesion sites (30 μg/day; 3 consecutive days) or intravenously via the tail vein (5 mg/kg; 3 times every other day), and macroscopic inflammatory signs of the skin, such as erythema and crust formation, were recorded. Mice were videotaped, and the duration of skin scratching behavior was measured.
resultsIntravenously injected 3E1 accumulated in dermal nerve fibers and dorsal root ganglia. By both routes of administration, the 3E1-treated group showed a shorter duration of scratching behavior in the first week and a faster improvement in dermatitis in the second week after the initial injection than the control group.
conclusion3E1 has potential as a therapeutic agent for atopic dermatitis owing to its antipruritic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.